undefined, Combination Studies With The Vascular Disrupting Agent CA4P,
undefined, Combination Studies With The Vascular Disrupting Agent CA4P,
undefined, Combination Studies With The Vascular Disrupting Agent CA4P, undefined, Combination Studies With The Vascular Disrupting Agent CA4P,

This work represents studies carried out at Mount Vernon Hospital and UCL, and sponsored by Cancer Research UK, between 2003 and 2006. Phase I/II Clinical trial studies of the vascular disrupting agent Combretastatin A4 Phosphate (CA4P) are presented - in combination with cytotoxic chemotherapy (Paclitaxel and Carboplatin), and radioimmunotherapy. Dynamic Contrast Enhanced MRI data from the studies is presented and discussed, and a supporting immunohistochemistry correlation study of vascular markers... Mehr

chart preloader
1 Woche 3 Monate 6 Monate 1 Jahr
Gewünschter Preis:
CHF
E-Mail Adresse:
Newsletter abonnieren
Preis-Alarm aktivieren